Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
norfloxacin + synbiotic
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination of norfloxacin, a broad-spectrum fluoroquinolone antibiotic, with synbiotics (probiotics and prebiotics). Norfloxacin works by inhibiting DNA gyrase and topoisomerase IV enzymes necessary for bacterial DNA replication, transcription, repair, and recombination. The synbiotic component would theoretically help restore beneficial gut bacteria that might be affected by the antibiotic treatment.
02
Targets
DNA gyraseTopo IV (Bacterial Topoisomerase IV)
Beyond the preview
Go deeper on norfloxacin + synbiotic.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on norfloxacin + synbiotic.